Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,801.08 -724.95 (-1.12%) CMC Crypto 200
1,327.31 -69.23 (-4.95%)
Oncolytics Biotech Inc. (ONCY)
After hours:
| Previous close | 1.0800 |
| Open | 1.0900 |
| Bid | 1.0600 x 100 |
| Ask | 1.1000 x 400 |
| Day's range | 1.0600 - 1.1000 |
| 52-week range | 0.8800 - 3.3900 |
| Volume | |
| Avg. volume | 370,829 |
| Market cap | 82.726M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3000 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.84 |
PR NewswireOncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois. Details on the abstracts and poster presentation are shown below.
PR NewswireOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
CNW GroupOncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President and Chief Executive Officer Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place on April 15, 2024. Additional details on the panel presentation can be found below.
